Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 44, Issue 3, 1999, Pages 197-205

  Takeda, Shigemasa ^a   Ueshiba, Hajime ^a   Hattori, Yoshinori ^a   Irie, Minoru ^b  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

Cilnidipine; Hypertension; NIDDM; Urinary C peptide; Urinary catecholamines

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE DERIVATIVE; CILNIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; GLIBENCLAMIDE; INSULIN; NILVADIPINE; NORADRENALIN;

ADRENALIN URINE LEVEL; ADULT; AGED; ARTICLE; CATECHOLAMINE URINE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET; DOPAMINE URINE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN URINE LEVEL;

AGED; C-PEPTIDE; CALCIUM CHANNEL BLOCKERS; CATECHOLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; DOPAMINE; EPINEPHRINE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; NOREPINEPHRINE;

EID: 0033029327     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(99)00053-4     Document Type: Article

References (43)

1. Honwing H., Frankel K.M.A., Strubbe J.H., Van Suylichem P.T.R., Steffens A.B.S. Role of the sympathoadrenal system in exercise-induced inhibition of insulin secretion: effects of islet transplantation. Diabetes. 44:1996;565-571.
2. Turgan N., Coker C., Hamulu F., Elmaci S., Ylmaz C., Ersez B., Islegen C. Glucose metabolism and catecholamine responses during physical exercise in non-insulin-dependent diabetes. Eur. J. Clin. Chem. Clin. Biochem. 34:1996;683-689.
3. Vitek V., Lang D.J., Cowley R.D. Admission serum insulin and glucose levels in 247 accident victims. Clinica. Cimica. Acta. 95:1979;93-104.
4. Crock P.A., Ley C.J., Martin I.K., Alford F.P., Best J.D. Hormonal and metabolic changes during hypothermic coronary artery bypass surgery in diabetic and non-diabetic subjects. Diabet. Med. 5:1987;47-52.
5. Yki-Jarvinen H., Makimattila S. Insulin resistance due to hyperglycemia: an adaptation protecting insulin-sensitive tissue. Diabetologia. 40:1997;S141-S144.
6. Kaplan N.K. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 149:1989;1520-1541.
7. Krieger D.R., Landsberg L. Mechanisms in obesity-related hypertension: role of insulin and catecholamines. Am. J. Hypertens. 1:1988;84-90.
8. Knatterud G.L., Klimt C.R., Levin M.E., Jacobson M.E., Goldner M.G. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: university group diabetes program VI. Mortality and selected nonfatal events with insulin treatment. J. Am. Assoc. 240:1978;37-42.
9. Kannel W.B., Cupples A., D'Agostino R.B., Stokes III J. Hypertension, antihypertensive treatment and sudden coronary death: the Framingham study. Hypertension. 11(Suppl II):1988;45-50.
10. Fusilli L., Lyons M., Patel B., Torres R., Hernandez F., Regan T. Ventricular vulnerability in diabetes and myocardial norepinephrine release. Am. J. Med. Sci. 296:1989;207-214.
11. Gerich J.E., Karam J.H., Forsham P.H. Stimulation of glucagon secretion by epinephrine in man. J. Clin. Endocrinol. Metab. 37:1973;479-481.
12. Beard J.C., Weinberg C., Pfeifer M.A., Best J.D., Halter J.B., Porte D. Jr Interaction of glucose and epinephrine in the regulation of insulin secretion. Diabetes. 31:1982;802-807.
13. Ostenson C.-G., Hjemdahl P., Efendic S. Release of catecholamines is increased but does not contribute to the impaired insulin secretion in the perfused pancreata of diabetic rats. Pancreas. 8:1993;34-38.
14. Ortiz-Alonso F.J., Herman W.H., Zobel D.L., Perry T.J., Smith M.J., Halter J.B. Effect of epinephrine on pancreatic,β- and α-cell function in patients with NIDDM. Diabetes. 40:1991;1194-1202.
15. 2+ channels in evoked release of norepinephrine from sympathetic neurons. Science. 239:1988;57-61.
16. Clasbrummel B., Osswald H., Illes P. Inhibition of noradrenaline release by ω-conotoxin GVIA in the rat tail artery. Br. J. Pharmacol. 96:1989;101-110.
17. Yoshimoto R., Dohmoto H., Yamada K., Goto A. Prolonged inhibition of vascular contraction and calcium influx by the novel 1,4-dihydropyridine calcium antagonist cilnidipine (FRC-8653). Jpn. J. Pharmacol. 56:1991;225-229.
18. Ikeda K., Hosono M., Iida H., Ohnishi H. Antibypertensive and cardiovascular profiles of a newly synthesized dihydropyridine derivative 2-methoxyethyl (E)-3-phenyl-2-propen-1-yl(±)-1,4-dihydro-2,6-dimethyl-4-(3-nitropheny) pyridine-3,5-dicarboxylate(FRC-653). Pharmacometrics. 44:1992;433-442.
19. 2+ channel in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther. 280:1997;1184-1194.
20. Ishii M., Matsuoka H., Iimura O. et al. Efficacy and safety of FRC-8653 (cilnidipine) in the long-term treatment of patients with essential hypertension. Jpn. Pharmacol. Thre. 21:1993;123-153.
21. Tominaga M., Ohya Y., Kobayashi K. et al. Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonists, cilnidipine. Cardiovasc. Drugs Ther. 11:1997;43-48.
22. Mandai T., Ozawa H., Yano A. et al. Measurement of urinary sodium and potassium excretion with the proportional sampling device (partition cup) compared with the 24-h whole urine collection. Jpn. J. Nephrol. 27:1985;815-823.
23. Young J.B., Landsberg L. Suppression of sympathetic nerves system during fasting. Science. 196:1977;1473-1475.
24. Young J.B., Landsberg L. Stimulation of the sympathetic nerves system during sucrose feeding. Nature Lond. 269:1977;615-617.
25. Forst T., Pfutzner A., Jahn C., Schmitz H., Lichtwald K., Beyer J., LeLnert H. Decreased sympatho-adrenal activity in diabetic patients with autonomic dysfunction following mental stress. J. Auton. Nerv. Syst. 61:1996;31-36.
26. Vgontzas A.N., Blxler E.O., Papanicolaou D.A. et al. Rapid eye movement sleep correlates with the overall activities of the hypothalamic-pituitaryadrenal axis and sympathetic system in healthy humans. J. Clin. Endocrinol. Metab. 82:1997;3278-3280.
27. Boomsma F., Alberts G., Eijk L.V., Man in't Veid A.J., Schalekamp A.D.H. Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. Clin. Chem. 39:1993;2503-2508.
28. Abdel-Aziz M.T., Abdel-Kader M.M., Rashad M.M. Urinary catecholamines and their metabolizes in diabetes. Acta. Biol. Med. Germ. 34:1975;1643-1650.
29. Brunetti P., Massi-Benedetti M., Puxeddu A. et al. Variation induced by a 3-day application of the artificial β-cell on glucagon, growth hormone and catecholamine secretion, glycosylated hemoglobin and erythrocyte 2,3-diphosphoglycerate concentration. Horm. Metab. Res. Suppl 8:1979;81-86.
30. Hoeldtke R.D., Cilmi K.M. Norepinephrine secretion and production in diabetic autonomic neuropathy. J. Clin. Endocrinol. Metab. 59:1984;246-252.
31. Kazman P.L., Hulthen U.L., Hokfelt B. The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma rennin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension. Br. J. Clin. Phamacol. 21:1986;633-640.
32. Harano Y., Kageyama A., Hirose J. et al. Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. Metabolism. 44:1995;315-319.
33. Leenen F.H.H., Fourney A. Comparison of the effects of amlodipine and diltiazem on 24-h blood pressure, plasma catecholamines and left ventricular mass. Am. J. Cardiol. 78:1996;203-207.
34. Hosono M., Fujii S., Hiruma T. et al. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn. J. Pharmacol. 69:1995;127-134.
35. Minami J., Toshihiko I., Kawano Y., Numabe A., Matsuoka H. Comparison of 24-h blood pressure, heart rate and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J. Cardiovasc. Pharmacol. 32:1998;331-336.
36. Minami J., Toshihiko I., Higashi T., Numabe A., Matsuoka H. Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Hypertens. Res. 21:1998;215-219.
37. Blix P.M., Boddie-Willis C., Landau R.L., Rochman H., Rubenstein A.H. Urinary C-peptide: an indicator of β-cell secretion under different metabolic conditions. J. Clin. Endocrinol. Metab. 54:1982;574-580.
38. Hoogwerf B.J., Barbosa J.J., Bantle J.P., Laine D., Goetz F.C. Urinary C-peptide as a measure of β-cell function after a mixed meal in healthy subjects: comparison of 4-H urine C-peptide with serum insulin and plasma C-peptide. Diabetes Care. 6:1983;488-492.
39. Ferannini E., Buzzigoli G., Giorico M.A. et al. Insulin resistance in essential hypertension. New Engl. J. Med. 317:1987;350-357.
40. Reaven G.M. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia and coronary heart disease. Am. Heart. J. 121:1991;1283-1288.
41. DeFronzo R.A., Ferrannini E. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 14:1991;173-194.
42. W.H.H. Sheu, A.L. Swislocki, B. Hoffman, Y.D.I. Chen, G.M. Reaven, Comparison of the effects of atenolol and nifedipine on glucose, insulin and lipid metabolism in patients with hypertension, Am. J. Hypertens. (1991) 199-205.
43. limura O., Shimamoto K., Masuda A. et al. Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives. J. Diabet. Compl. 9:1995;215-219.